As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a ...
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of ...
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...
Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...
In March 2026, the US Department of Justice (DOJ) announced criminal charges against medical device company ExThera Medical Corporation and its ...
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues; Re ...
On May 14–15, U.S. President Donald Trump visited China for the first time in eight years, meeting President Xi Jinping in ...
THOUSAND OAKS, Calif., June 1, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a ...
Product Revenue -- $0.4 million, decreased from $0.8 million, reflecting limited commercial activity and ongoing investment ...
A USCIS backlog that stood at 3.5 million cases a decade ago has now surged past 11.6 million, leaving millions of immigrants, workers, and families waiting indefinitely for decisions that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results